ACTRN12614000812695

This Phase II study seeks to determine the effectiveness of using the patient’s own adipose-derived mesenchymal stem cell to repair cartilage defects. 40 participants will be recruited. Half will have arthroscopic microfracture and mesenchymal stem cells administered weekly for up to 13 weeks post surgery, while the other half will have arthroscopic microfracture alone.